Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial

详细信息    查看全文

• 作者：Dr Manel Sabaté ; MD^a ; ^{masabate@clinic.ub.es" class="auth_mail" title="E-mail the corresponding author} ; Salvatore Brugaletta ; MD^a ; Angel Cequier ; MD^b ; André ; s Iñ ; iguez ; MD^c ; Antonio Serra ; MD^d ; Pilar Jimé ; nez-Quevedo ; MD^e ; Vicente Mainar ; MD^f ; Gianluca Campo ; MD^g ; Maurizio Tespili ; MD^h ; Peter den Heijer ; MDⁱ ; Armando Bethencourt ; MD^j ; Nicolá ; s Vazquez ; MD^k ; Gerrit Anne van Es ; PhD^l ; Bianca Backx ; RN^l ; Marco Valgimigli ; MD^m ; ⁿ ; Prof Patrick W Serruys ; MD^o
• 刊名：The Lancet
• 出版年：2016
• 出版时间：23-29 January 2016
• 年：2016
• 卷：387
• 期：10016
• 页码：357-366
• 全文大小：507 K

文摘

Data for the safety and efficacy of new-generation drug-eluting stents at long-term follow-up, and specifically in patients with ST-segment elevation myocardial infarction, are scarce. In the EXAMINATION trial, we compared everolimus-eluting stents (EES) with bare-metal stents (BMS) in an all-comer population with ST-segment elevation myocardial infarction. In this study, we assessed the 5-year outcomes of the population in the EXAMINATION trial.

Methods

In the multicentre EXAMINATION trial, done in Italy, Spain, and the Netherlands, patients with ST-segment elevation myocardial infarction were randomly assigned in a 1:1 ratio to receive EES or BMS. The random allocation schedule was computer-generated and central randomisation (by telephone) was used to allocate patients in blocks of four or six, stratified by centre. Patients were masked to treatment assignment. At 5 years, we assessed the combined patient-oriented outcome of all-cause death, any myocardial infarction, or any revascularisation. Analysis was by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00828087.

Findings

1498 patients were randomly assigned to receive either EES (n=751) or BMS (n=747). At 5 years, complete clinical follow-up data were obtained for 731 patients treated with EES and 727 treated with BMS (97% of both groups). The patient-oriented endpoint occurred in 159 (21%) patients in the EES group versus 192 (26%) in the BMS group (hazard ratio 0·80, 95% CI 0·65–0·98; p=0·033). This difference was mainly driven by a reduced rate of all-cause mortality (65 [9%] vs 88 [12%]; 0·72, 0·52–0·10; p=0·047).

Interpretation

Our findings should be taken as a point of reference for the assessment of new bioresorbable polymer-based metallic stents or bioresorbable scaffolds in patients with ST-segment elevation myocardial infarction.

Funding

Spanish Heart Foundation.